This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for August 17th
by Zacks Equity Research
CGNT, AUD, and CBAN have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2022.
Cognyte Software Ltd. (CGNT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cognyte Software Ltd. (CGNT) delivered earnings and revenue surprises of -758.33% and 22.83%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 18th
by Zacks Equity Research
AGNC, BEP, and CGNT have been added to the Zacks Rank #5 (Strong Sell) List on April 18, 2022.
Cognyte Software Ltd. (CGNT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cognyte Software Ltd. (CGNT) delivered earnings and revenue surprises of -27.27% and 3.20%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Oblong, Inc. (OBLG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oblong, Inc. (OBLG) delivered earnings and revenue surprises of 10% and 14.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cognyte Software Ltd. (CGNT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cognyte Software Ltd. (CGNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jabil (JBL) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Jabil's (JBL) third-quarter fiscal 2021 results reflect benefits from contract wins in healthcare, mobility, cloud-connected devices and semi-cap despite supply chain headwinds.
Zacks.com featured highlights include: Ecopetrol, TheStreet, Cogentix, Fortuna Silver and CPI Aerostructures
by Zacks Equity Research
Zacks.com featured highlights include: Ecopetrol, TheStreet, Cogentix, Fortuna Silver and CPI Aerostructures
5 Bargain Breakout Stocks Offering Amazing Returns
by Swarup Gupta
This involves zeroing in on stocks trading within a tight range and buying them when they step out of this band.
Laborie Medical Technologies to Acquire Cogentix Medical
by Zacks Equity Research
Laborie Medical Technologies will buy all of the outstanding shares of Cogentix Medical (CGNT) for a net worth of $239 million.
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
by Zacks Equity Research
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?
by Zacks Equity Research
Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.
4 Growth Stocks to Pick From a Choppy MedTech Market
by Zacks Equity Research
In the wake of the volatile political scenario and taking a few favorable metrics into account, these MedTech stocks stand out as the most suitable picks.
Cogentix Medical (CGNT) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
Cogentix Medical (CGNT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.
AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.
Masimo RAS-45 Full-Market Release to Boost Respiratory Care
by Zacks Equity Research
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Baxter Announces Launch of DeviceVue System for Sigma Pumps
by Zacks Equity Research
Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.
ABIOMED (ABMD) Banks on Impella Platform, Forex a Concern
by Zacks Equity Research
ABIOMED (ABMD) is focusing heavily in its proprietary Impella Platform to enhance customer base.
Allscripts Rides High on Product Launches Amid Rising Costs
by Zacks Equity Research
Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
Cerner's (CERN) stable position provides solid growth opportunities in the revenue cycle management (RCM) suite of solutions.
Here's Why Investors Should Buy Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.
BD (BDX) Inks New Deal to Strengthen Foothold in STI Space
by Zacks Equity Research
BD (BDX) is a leading player in providing solutions for women's health and sexually transmitted infections. Its latest development is likely to lend the company a competitive edge in the niche space.
Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance
by Zacks Equity Research
Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.
Varian Conducts Clinical Workshop, Strengthens Algeria Hold
by Zacks Equity Research
Varian (VAR) has 30 systems operating in Algeria at the moment. The latest development signifies the company's long-term goal of serving six million cancer patients every year.
AngioDynamics' BioFlo Platform Strong, Debt Levels High
by Zacks Equity Research
AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.